Q-omics provides the consensus-scored TRIM54 profile across patient tissues and cancer cell-line models. TRIM54 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TRIM54 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, TRIM54 RNA expression shows 13,014 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LUAD, THCA, and HNSC as cancer lineages where TRIM54 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM54 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM54 survival associations across molecular data types. TRIM54 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM54 RNA expression–survival associations across cancer types. High TRIM54 expression shows unfavorable associations in LIHC, KICH, STAD, ESCA and KIRC, but favorable associations in LUAD. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for TRIM54 RNA expression.
This table summarizes TRIM54 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM54. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM54 shows lower tumor expression in KICH and higher tumor expression in THCA, COAD, LUAD, KIRC and LIHC. The THCA box plot shows higher TRIM54 RNA expression in tumor versus normal tissue (log2 FC = +1.612, t-test p < 0.001).
This table shows molecular features associated with TRIM54 in patient tissues and cancer cell lines. In patient samples, TRIM54 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM54 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
